Combination therapy with CAR-T cells and BET inhibitors (i.e., JQ-1) suppressed PD-L1 and TIM-3 expression and tumor cell growth in GBM, AML, and ovarian cancer models, thus improving the efficacy of immunotherapy by both rescuing CAR-Ts from exhaustion and making the tumor mileu more hospitable to T cells [191,193,194]. The gene discussed is HAVCR2; the disease is neoplasm.